We came across a bullish thesis on DexCom, Inc. (DXCM) on Substack by Na’s Substack. In this article, we will summarize the ...

This video by [Becky Stern] is all about comparing two of the most popular continuous glucose monitors (CGMs): the Abbott Libre 3 and the Dexcom G7. Both the Libre 3 and the G7 come with spring ...

Dexcom, known for its glucose sensors and broader health tech, is partnering with Oura to integrate its data into the Oura ecosystem ... as well as the Dexcom G7 for those with hypoglycemia ...

In earnings calls, diabetes tech companies had less to say about tariffs and focused more on future growth.

Dexcom reaffirmed its 2025 revenue guidance of ... with evident confidence in key initiatives like the 15-day G7 launch. Revenue growth accelerated to 14% in Q1 2025 from 8% in Q4 2024.

In the first quarter, Dexcom’s G7 system continued its robust momentum. Accelerated conversion of the installed base for G7 manufacturing is driving strong revenue performance and improving ...

“As we progress through 2025, we will advance our product portfolio with the launch of our Dexcom G7 15-Day system and continue to advocate for expanded global access to our glucose biosensors ...

Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Dexcom (Nasdaq:DXCM) announced today that it promoted Jake Leach to the role of president, in addition to his post as COO.

Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered ...